Details
| Originalsprache | Englisch |
|---|---|
| Seiten (von - bis) | 64-69 |
| Seitenumfang | 6 |
| Fachzeitschrift | European Journal of Health Economics |
| Jahrgang | 5 |
| Ausgabenummer | 1 |
| Frühes Online-Datum | 24 Sept. 2003 |
| Publikationsstatus | Veröffentlicht - Feb. 2004 |
Abstract
Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.
ASJC Scopus Sachgebiete
- Volkswirtschaftslehre, Ökonometrie und Finanzen (insg.)
- Volkswirtschaftslehre, Ökonometrie und Finanzen (sonstige)
- Medizin (insg.)
- Health policy
Ziele für nachhaltige Entwicklung
Zitieren
- Standard
- Harvard
- Apa
- Vancouver
- BibTex
- RIS
in: European Journal of Health Economics, Jahrgang 5, Nr. 1, 02.2004, S. 64-69.
Publikation: Beitrag in Fachzeitschrift › Übersichtsarbeit › Forschung › Peer-Review
}
TY - JOUR
T1 - Comparison of estimated medical costs among patients who are defined as having rheumatoid arthritis using three different standards
AU - Ruof, Jörg
AU - Hülsemann, Jan L.
AU - Mittendorf, Thomas
AU - Handelmann, Silke
AU - Aultman, Rick
AU - Von Der Schulenburg, J. Matthias
AU - Zeidler, Henning
AU - Merkesdal, Sonja
PY - 2004/2
Y1 - 2004/2
N2 - Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.
AB - Accurate estimation of medical care costs raises a host of challenging issues. We examined whether pure administrative claims data without clinical validation of diagnosis allow reasonable estimation of disease-related costs in rheumatoid arthritis (RA). Three patient groups were examined: patients with clinically confirmed RA (group A, n=338), patients with likely RA (administrative claims data reported the diagnosis of RA and patients were treated with disease modifying antirheumatic drugs, DMARDs; group B, n=303), and patients with possible RA (same as group B but patients had no DMARD treatment; group C, n=685). The payer's perspective was taken for this analysis. Only direct costs were included in the analysis. Cost data and data for several covariates were obtained from a major German statutory health insurance plan, the AOK Niedersachsen. A patient-per-patient microcosting approach was performed. A repeated measures, fixed effect model was applied to examine differences between the three study groups. Mean±SEM annual RA-related direct costs were € 2,017±183 per patient-year in group A, € 1763±192 in group B, and € 805±58 in group C. Outpatient (inpatient) costs were € 1636 (328) in group A, € 1344 (340) in group B, and € 546 (136) in group C. DMARD costs were by far the single most important cost driver in groups A and B. The difference in total RA-related direct cost between groups A and B was not significant whereas the differences between groups A and C (group B and C respectively), were significant. Pure administrative claims data allowed for an accurate estimate of disease-related costs-in RA patients that received DMARD therapy. However, the high number of patients for whom administrative claims data listed the diagnosis RA, but no DMARD treatment was given poses a challenge for further research.
KW - Cost of illness
KW - Health economics
KW - Rheumatoid arthritis
UR - http://www.scopus.com/inward/record.url?scp=1542284168&partnerID=8YFLogxK
U2 - 10.1007/s10198-003-0203-4
DO - 10.1007/s10198-003-0203-4
M3 - Review article
C2 - 15452767
AN - SCOPUS:1542284168
VL - 5
SP - 64
EP - 69
JO - European Journal of Health Economics
JF - European Journal of Health Economics
SN - 1618-7598
IS - 1
ER -